As a cardiologist I would follow our current ESC guidelines and they say if you have a variable ECG with AF of 30 seconds you should handle this as AF and if there is a CHA₂DS₂-VASc score one or bigger one, you should anticoagulate this patient. I think in five years, we, of course, will have the results, the final results of FIND-AF2. We expect the results for 2027. And if we can show that intensified and prolonged rhythm monitoring reduces hard endpoints, such as recurrent ischemic stroke or systemic embolism...
As a cardiologist I would follow our current ESC guidelines and they say if you have a variable ECG with AF of 30 seconds you should handle this as AF and if there is a CHA₂DS₂-VASc score one or bigger one, you should anticoagulate this patient. I think in five years, we, of course, will have the results, the final results of FIND-AF2. We expect the results for 2027. And if we can show that intensified and prolonged rhythm monitoring reduces hard endpoints, such as recurrent ischemic stroke or systemic embolism. Wearables can play a role because they are patient-centered, they are accessible and I think they could easily complement current rhythm monitoring strategies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.